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Medication adherence and health-related quality of life among 
patients with chronic obstructive pulmonary disease
This study evaluated medication adherence and health-re-
lated quality of life (HRQoL) of Slovenian patients with 
chronic obstructive pulmonary disease (COPD) and exam-
ined the factors associated with HRQoL. Demographic and 
therapy information was collected from 65 patients through 
interviews. The St. George’s Respiratory Questionnaire and 
the Morisky Medication Adherence Scale were used to 
evaluate HRQoL and adherence, resp. A multiple linear re-
gression model was used to assess the association between 
the factors and HRQoL. The mean St. George’s Respiratory 
Questionnaire score (range 0–100, with higher scores indi-
cating lower HRQoL) was 41.4. COPD affected patients’ 
daily activities more than their social and psychological 
functioning. Slightly more than 53 % of the patients were 
optimally adherent, while 12 % were non-adherent. Pa-
tients with lower HRQoL had a larger number of medica-
tions for concomitant diseases, experienced COPD exacer-
bation in the last year, and had less education. No 
statistically significant correlation was found between 
medication adherence and HRQoL.
Keywords: chronic obstructive pulmonary disease, health-
related quality of life, adherence
Chronic obstructive pulmonary disease (COPD) is a common, preventable and treat-
able disease. It is characterized by persistent respiratory symptoms, such as shortness of 
breath, chronic cough and mucus hypersecretion, with airflow limitation due to airway or 
alveolar abnormalities typically arising from significant exposure to noxious particles or 
gases (1). COPD was the fourth leading cause of death in 2010, and at that time it was pro-
jected to be the third leading cause by 2020. However, this level was already reached by 
2012. More than 3 million people died of COPD in 2012, accounting for 5.6 % of all deaths 
globally (1, 2). In Slovenia, COPD leads to 500–600 deaths yearly, representing 3 % of deaths 
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When COPD severity is being assessed, the goals are to determine the level of airflow 
limitation (characterized by forced expiratory volume in the first second, FEV1), the risk of 
future events (e.g., exacerbations) and the impact of the disease on the patient’s health-re-
lated quality of life (HRQoL) (1). COPD primarily affects the lungs, but it also causes struc-
tural and functional changes in other organs, leading to symptoms that have no immedi-
ate relationship to expiratory airflow limitation (e.g., fatigue). Consequently, estimating 
HRQoL is valuable because it reflects the overall impact of the disease and treatment on 
the patient’s life.
One factor that often affects HRQoL of patients undergoing long-term therapies is 
medication adherence. COPD treatment typically involves multiple medications, which 
can lead to adherence problems. The chronic nature of the disease and periodic remission 
of symptoms also contribute to increased risk of adherence issues in patients with COPD 
(3). Information on HRQoL and adherence is necessary for planning appropriate interven-
tions, but such information is lacking for the COPD population in Slovenia.
Thus, the aims of this study were to evaluate medication adherence and HRQoL of 
Slovenian patients with COPD and to examine the factors potentially associated with 
HRQoL.
EXPERIMENTAL
A cross-sectional design was used, with eligible patients being recruited in commu-
nity pharmacies. Demographic characteristics and information about therapy were col-
lected from participants, who were also asked to complete medication adherence and 
HRQoL questionnaires. 
Sample
Patients who were eligible for the study had to be at least 18 years old, had at least one 
prescribed inhaler and confirmed that they had COPD. For measurement of adherence, 
they had to be taking at least one COPD medication intended for regular use for at least 3 
months. 
Sample size was calculated based on the multiple linear regression requirement of at 
least 10 subjects per independent variable (4). In addition to adherence score, five other 
factors that could influence HRQoL (education, age, current smoking status, number of 
concomitant medications for other diseases, presence of exacerbations) were included. 
Consequently, a sample of at least 60 patients was required.
Study conduct
From public pharmaceutical institutions (the predominant form of pharmacy owner-
ship in Slovenia, consisting of multiple community pharmacies), 16 of the most frequently 
visited pharmacies regionally dispersed throughout Slovenia were identified. Community 
pharmacists in the 16 chosen pharmacies recruited eligible patients when dispensing medi-
cation for COPD. Patients who agreed to participate were directed to a pre-trained re-
searcher, who explained the study aims, method and benefits. Participants signed written 
informed consents. 
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Patients were asked to provide basic demographic (sex, age, education level, smoking 
status) and therapy information (therapy duration, names of used medications, dosage, 
number of concomitant medications for other diseases). In addition, the presence of exacer-
bations of COPD in the last year, defined as an emergency room visit, hospitalization or 
taking an oral glucocorticoid in the last year, was identified (1). Patients’ COPD diagnosis 
and therapy information were confirmed by accessing their health records and pharmacy 
claims data. After an introductory interview, patients immediately self-completed and 
returned questionnaires that were used to evaluate medication adherence and HRQoL.
The study was conducted in September 2014 and February 2015 in compliance with 
the Declaration of Helsinki. The National Medical Ethics Committee (Komisija RS za medi-
cinsko etiko, Ministrstvo za zdravje, Štefanova 5, 1000 Ljubljana) approved the study.
Questionnaires
The St. George’s Respiratory Questionnaire (SGRQ) was used to assess patients’ 
HRQoL. The questionnaire consists of 50 items divided into three components (symptoms, 
activity and impacts). Items have different response categories. For symptoms, patients 
took the preceding 12-month period into account. A score for each of the three components 
was calculated. A total score reflecting the impact of the disease on overall health status 
was also calculated. Scores ranged from 0 to 100, with higher scores indicating more limi-
tations (lower HRQoL) (5).
Medication adherence was evaluated using the Morisky Medication Adherence Scale 
(MMAS-8), an eight-item self-reported measure of medication-taking behaviour (6−8). 
MMAS-8 scores can range from 0 to 8 points. Patients who scored < 6 points, 6 to < 8 points 
and 8 points were regarded as having low, medium and high adherence, resp. When an-
swering the questions, patients accounted for all the medications they regularly took for 
COPD.
Statistical analysis
Standard descriptive statistics measures [mean, standard deviation (SD), median, in-
terquartile range (IQR), min, max] were used. The Kolmogorov-Smirnov test was applied 
to test the normality of the distribution of variable scores. To estimate the association be-
tween potential predictors and COPD impact on the quality of life, a multiple linear re-
gression model with the patients’ HRQoL score as a dependent variable was used. HRQoL 
scores followed a normal distribution. MMAS-8 score (low, medium, high), education (ele-
mentary school, high school, college/university), age, current smoking status (yes/no), 
number of concomitant medications for other diseases and the presence of exacerbations 
were set as factors. In cases of categorical variables with more than two categories, dummy 
variables (dichotomous variables that take the value of either 0 or 1 to indicate the absence 
or presence of some categorical effect) were used. Sex was not included in the model since 
the preliminary analysis did not show any significant differences in HRQoL scores be-
tween male and female patients (t = 0.472, p = 0.639). The backward method for selection of 
predictive variables with criterion probability of F-to-remove ≥ 0.1 was employed (one 
predictive variable was removed at each step based on the largest p value of F). Statistical 
analysis was performed in SPSS V.23, and a p-value < 0.05 was considered to indicate sta-
tistical significance. 
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Altogether, 65 patients were recruited at community pharmacies. Table I presents the 
patients’ demographic and therapy information.
The median number of medications for COPD treatment was two. Patients mostly 
received anticholinergics (64 %), a long-acting β-agonist/anticholinergic combination (50 
%) and a combination of inhaled glucocorticoid and long-acting β-agonist (50 %). Very few 
patients used theophylline (9 %) or oral glucocorticoids (6 %).
HRQoL
Table II presents the scores of the SGRQ per component as well as the total score. 
Higher scores indicate lower HRQoL. Patients scored best on the “impact” component, 
which reflects the impact of COPD on social and psychological functioning. Their scores 
Table I. Demographic and therapy information of 65 included patients
Characteristic % or mean (± SD) or median (IQR)
Sex (N = 65) 32.3 % female, 67.7 % male
Age (N = 64) mean 70.1 (± 10.3) yrs
Education level (N = 65)
Elementary school 15.4 %
High school 70.8 %
College/university 13.8 %
Current smoker (N = 65) 24.6 %
Duration of COPD treatment (N = 61)
< 1 years 10.8 %
1–5 years 40.0 %
6–10 years 21.5 %
> 10 years 21.5 %
No. of medications for COPD (N = 65) median 2 (1)
No. of concomitant medications for other diseases (N = 57) median 3 (4)
Exacerbations in the past year (N = 65)
Emergency room visits 20.0 %
Hospitalisation 23.1 %
Oral glucocorticoid treatment 23.1 %
At least one of the above (emergency room visit, hospitalisation 
or oral glucocorticoid treatment) 38.5 %
COPD − chronic obstructive pulmonary disease, IQR − interquartile range
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were worse on the “symptoms” component, which indicates the frequency and severity of 
symptoms. The worst scores were found in the “activity” component, which centers on 
daily activities that cause breathlessness or are limited by it.
The mean total SGRQ score summarizing the impact of the disease on the overall 
health status was 41.4. Arpinelli et al. (9) reviewed studies using SGRQ to measure HRQoL 
in patients with COPD and reported similar total scores ranging from 40 to 50. The indi-
vidual component scores were not so unanimous, as reported by Ekici et al. (10), but all 
studies had a similar ordering of components: “activity” scores were the highest, followed 
by “symptoms” and “impact” scores. This finding is not surprising since COPD patients 
are mostly older patients who also have other non-respiratory diseases (e.g., osteoporosis, 
cardiovascular diseases, metabolic syndrome, depression). Such comorbidities, paired 
with dyspnoea, cause these patients to have reduced physical activity, leading to a dimini shed 
physical condition. This situation is reflected in the lowest HRQoL for the “activity” and 
“symptoms” components (11).
Medication adherence
The average MMAS-8 score (± SD) on a 1–8 scale was 7.3 ± 1.2. The proportions of pa-
tients with high, medium and low adherence rates were 53, 35 and 12 %, resp. No signifi-
cant differences in adherence scores were found between male and female patients (t = 
1.345, p = 0.192).
The current study showed that 53.4 % of the COPD patients were optimally adherent 
to the treatment (8 points on MMAS-8). Other studies report similar adherence rates of 
40–60 % (3). These studies mostly used self-reporting methods for measuring adherence. 
Patient’s self-reports may overestimate their adherence due to social desirability bias, 
which leads patients to give socially desirable responses rather than responses that reflect 
their true situation (3). Patients may worry that giving honest answers could influence 
their relationship with their health-care provider and their future care. Therefore, they 
give the answers that they think are expected. In this study, this bias was minimized by 
having researchers rather than health-care providers collect the information. However, an 
impact on the overestimation of adherence rates cannot be totally ruled out, and the per-
centage of adherent patients under real-life conditions might be lower than what this study 
suggests.




Mean 49.8 53.7 31.6 41.4
Standard deviation 24.6 25.4 20.1 19.9
Min–max 0–95.0 0–93.3 0–73.7 2.0–79.4
SGRQ − St. George’s respiratory questionnaire
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Factors related to HRQoL
Table III shows the factors that were used in the final regression model using backward 
methods for factor selection. The model explained 58.5 % of the variance of the HRQoL 
score (R = 0.765, p < 0.001). Four factors were significantly associated with HRQoL: the num-
ber of concomitant medications (standardized β = 0.36), the presence of exacerbation in the 
past year (standardized β = 0.32), the education level (standardized β = −0.32) and current 
smoking status (standardized β = −0.27). For each additional medication, the SGRQ score 
increased by 2.36 points. Patients who experienced exacerbation in the last year had SGRQ 
scores that were 13.7 points higher on average, indicating lower HRQoL. Patients with uni-
versity or higher education had lower SGRQ scores than patients with an elementary school 
education, indicating better HRQoL. Patients who currently smoked displayed SGRQ 
scores that were 12.5 points lower on average, signifying higher HRQoL. Other factors, in-
cluding medication adherence, were not significantly associated with HRQoL.
Presence of exacerbations. − The presence of exacerbations increased the SGRQ score by 
13.7 points. This finding is in line with other studies, which defined exacerbations simi-
larly and determined their association with HRQoL. Miravitlles et al. (12) concluded that 
frequent exacerbations significantly impaired HRQoL of patients with moderate COPD.
Education. − People with a university education had SGRQ scores that were 21 points 
lower on average than people with an elementary school education in this study (adjusted 
Table III. Multivariate regression of HRQoL on patients’ demographic data, adherence and exacerbationsa
 Bb 95 % confidence interval
Standardized 
βc p-value
Constant 42.25 25.05, 59.44
Presence of exacerbation 13.74 3.68, 23.80 0.32 0.009
Current smoker −12.45 −23.82, −1.08 −0.27 0.033
Education  
(high school vs. elementary school) −12.24 −25.65, 1.17 −0.26 0.072
Education  
(university vs. elementary school) −20.85 −40.40, −1.30 −0.32 0.037
Adherence (low vs. high) −14.12 −29.53, 1.30 −0.22 0.071
No. of concomitant medications 
for other diseases 2.36 0.69, 4.03 0.36 0.007
HRQoL − health-related quality of life
a  Backward method for selection of factors with criterion probability of F-to-remove ≥ 0.1 was used. Excluded vari-
ables: age, dummy variable medium vs. high adherence due to criterion probability of F-to-remove < 0.1.
b  Unstandardized B coefficient indicates the individual contribution of each factor to the model. It represents the 
value for the regression equation for predicting the dependent variable from the factor. 
c  Standardized β coefficient presents the number of standard deviations that the outcome will change as a result of 
one standard deviation change in the factor. It allows comparisons of the magnitude of the coefficients to identify 
which has more of an effect on the dependent variable.
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for other factors). Higher education thus predicted higher HRQoL in patients with COPD. 
In the study by Miravitlles et al. (13), patients with a lower education level demonstrated 
higher prevalence of COPD as well as higher probability of late diagnosis, suggesting a 
worse disease course. Consequently, patients with a lower education level had poorer 
HRQoL, a finding replicated in this study.
Number of concomitant medications for other diseases. − For each additional medication 
treating concomitant diseases, the SGRQ score increased by 2.36 points, which indicates a 
decrease in HRQoL. Comorbidities often accompany COPD since it usually occurs in mid-
dle-aged regular smokers (1). Smoking is a risk factor for several diseases. Comorbidities 
most frequently accompanying COPD are cardiovascular diseases, osteoporosis, anxiety, 
depression and lung cancer (1). Van Manen et al. (14) studied the effect of COPD comor-
bidities on HRQoL and suggested that impairments in social and emotional functioning 
were exclusively related to the comorbidities and not to COPD itself. COPD principally 
affects physical functioning, vitality and general health domains.
Smoking status. − Smoking has been shown to have a significant effect on HRQoL of 
patients with COPD. Since tobacco smoking is considered the primary cause of COPD, 
smokers are expected to have lower HRQoL. However, smokers had a better quality of life 
than non-smokers in this study. This seemingly paradoxical finding might be explained by 
reverse causality. Patients with a worse disease state are more aware of negative smoking 
effects and therefore quit smoking, while patients whose COPD has not affected their 
HRQoL might still continue smoking. Because of reverse causality, it would be advisable 
to check the smoking history of COPD patients and not merely their current smoking 
status.
Adherence. − No significant relationship was found between medication adherence 
and HRQoL of patients with COPD in this study. Similar results were reported by Boland 
et al. (15), even after adjusting for disease severity, demographics and health lifestyle vari-
ables. Lack of a significant relationship might also be due to the small sample size or the 
categorization method. Although the association was not significant, the multiple linear 
regression coefficient suggests that less adherent patients experienced higher levels of 
HRQoL. Again, this finding might be due to reverse causality, with improved HRQoL pos-
sibly serving as a trigger for non-adherence in patients with COPD. Restrepo et al. (3) in-
vestigated common causes of poor adherence in patients treated for COPD. The most 
prominent cause was feeling well and consequently deciding to skip medications or for-
getting to take doses.
Limitations
This study has several possible limitations. A self-reported indirect measure of adher-
ence was used, which might overestimate adherence rates. No single method for measur-
ing adherence is considered a gold standard, and a combination of methods is advised to 
correctly validate adherence rates. A cross-sectional method for measuring adherence and 
HRQoL was employed. A longitudinal study would be a more reliable method to better 
understand the relation between these two variables. This approach would also allow for 
better control of reverse causality.
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CONCLUSIONS
More than half (53.4 %) of the Slovenian patients with COPD were optimally adherent 
to their treatment. COPD predominantly influenced patients’ daily activities, while their 
social and psychological functioning was less impaired. Patients’ HRQoL was negatively 
affected by an increasing number of concomitant medications, exacerbations in the past 
year and a lower education level. Medication adherence did not show a significant asso-
ciation with HRQoL.
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